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Doxycycline is a new tetracycline that is now in widespread
clinical use. It differs from the other tetracycline drugs in many
important respects including small daily dosage schedules,
essentially complete upper gastrointestinal absorption and excre-
tory characteristics that are independent of renal function. Our
studies demonstrate that in anephric patients and patients with
varying degrees of renal function the plasma t4 of biologically
active doxycycline is not significantly extended and that in such
a clinical situation the usual therapeutic regimen of the drug is
necessary. Clearance rate of the compound from the systemic
circulation by hemodialysis is only 10 mI/mm or less. In
addition, our investigations identify the importance of the
nonhepatic gastrointestinal pathway of elimination of doxycyc-
line from the systemic circulation. Doxycycline therefore appears
to be unique among the tetracyclines in that it may be utilized as
a drug of choice for the therapy of systemic infections when a
tetracycline compound is indicated in the clinical setting of
impaired renal function.
Pharmacocinetique de la doxycycline en l'absence de fonction
rénale. La doxycycline est une nouvelle tetracycline dont
l'usage clinique est maintenant largement répandu. Elle diffère
des autres tétracyclines a plusieurs égards importants parmi
lesquels Ia faible posologie quotidienne, l'absorption totale dans
Ia partie haute du tractus digestif et des modalités d'excrétion
indépendantes de Ia fonction rénale. Notre travail démontre que
chez les sujets anéphriques et les malades atteints d'insuffisance
rénale de sévérité variable Ia demie vie de la doxycycline
biologiquement active n'est pas significativement allongée et
que dans ces situations cliniques les modalités thérapeutiques
habituelles sont nécessaires. La clearance du compose observée
au cours de l'hémodialyse est égale ou inférieure a 10 mI/mm.
De surcroIt nos travaux identifient l'importance de la voie d'éli-
mination hépatique non intestinale de Ia doxycycline. La
doxycycline apparaIt donc être unique parmi les tétracyclines en
cc sens qu'elle peut être utilisée comme une drogue de choix
pour Ic traitment des infections systémiques quand une tétra-
cycline est indiquée et qu'il existe une alteration de la fonction
rénale.
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Doxycycline (a-6-deoxyoxytetracycline) is the most
recent of the tetracycline class of drugs to become
available for oral and intravenous therapy and is now
in widespread clinical use. It demonstrates a broad
spectrum of antibacterial activity [1—3] and from the
practical therapeutic point of view differs from the
other tetracyclines in a number of important respects.
It is a long-acting drug that is essentially completely
absorbed from the upper gastrointestinal tract [4—7];
smaller daily dosage schedules are required (100 to
300 mg orally) [5]; and studies reported from outside
the United States, where the drug has been thera-
peutically available for a longer period of time,
indicate that its biologic half-life (ti) appears to be
independent of renal function such that the usual
dosage regimen of this antibiotic is well tolerated by
patients with impaired renal function [8—10]. However,
in humans the mechanism of elimination from the
systemic circulation or the pathways of biodegradation
of the drug within the body have not been characterized.
Our studies were undertaken 1) to define the
duration of the drug's antibacterial activity in the
anephric state and in the presence of renal impair-
ment; 2) to evaluate its removal from the systemic
circulation by hemodialysis; and 3) to identify the
route of excretion or biodegradation of the drug in the
absence of renal function. One would expect that as
the urinary excretion of the drug decreases in renal
failure the percentage of unchanged and/or meta-
bolized doxycycline would increase in the feces.
However, the rate of the latter elimination or bio-
degradation has not been identified for doxycycline
and is of therapeutic importance. We therefore focused
particular attention on the intestinal excretory
characteristics of the drug since data obtained in
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experimental animals indicate that secretion of un-
changed drug into the bowel is a major route of
excretion [5, 6]. The drug was administered as
tritiated doxycycline to facilitate identification of
metabolites and routes of excretion.
Methods
All patients were admitted to the Metabolic
Investigative Unit of the Johns Hopkins Hospital.
Five anephric patients maintained on chronic hemo-
dialysis participated in the studies (Table 1). Following
an overnight fast and omission of antacids for a
24-hour period each patient was given a fat-free
breakfast and a solution containing 200 mg of
doxycycline base and 250 sCi of radioactivity. These
precautions prior to doxycycline administration
ensured essentially complete absorption of the drug
from the upper gastrointestinal tract [5, 6, 11]. No
further doses of doxycycline or any other antibacterial
or radioactive compound were administered during
the remainder of the study period. Plasma anti-
bacterial activity and radioactivity of the drug were
then followed for the next 120 hours. All stools were
saved for an 8- to 13-day period following administra-
tion of the compound. Repeat studies after a three-
month interval were undertaken in patients 1 and 2,
since stool collections were inadequate during their
first hospitalization.
Prior to these investigations, informed consent
was obtained from all the patients and the investiga-
tions were approved by the appropriate hospital
committee.
Each patient was hemodialyzed 72 hours after
doxycycline administration utilizing standard dialyzers
(Ku!) and drug clearance periods were measured in
four of the patients during hemodialysis.
Three patients with varying degrees of renal insuffi-
ciency also participated in the investigations (Table 2).
In these patients the dosage of doxycycline and the
precautions prior to drug administration were similar
to those already described. No stool collections were
undertaken but daily urine collections were made for
five days following administration of labeled doxy-
cycline. Plasma antibacterial activity and radioactivity
were investigated for 120 hours after drug admini-
stration.
Preparation and analysis of 3H-doxycycline. Radio-
active doxycycline labeled with tritium in the C-6
and C-13 positions by hydrogenation of methacycline
Table 1. Hematocrit and blood chemistry determinations in five anephric patients who received 200 mg
of 3H-doxycycline orally
Patient
No.
Age
years
Weight
kg
Hematocrit
%
Predialysis
creatinine
mg/100 ml
Total
protein
g/100 ml
Total
bilirubin
mg/100 ml
1 22 60 10 22 6.7 0.6
2 31 54 11 19 6.6 0.3
3 33 51 16 17 6.8 0.3
4 28 68 16 16 6.2 0.5
5 51 56 18 17 6.3 0.3
Table 2. Diagnosis, hematocrit and blood chemistry determinations in three patients with impaired renal function who
received 200 mg of 3H-doxycycline orally
Patient
No.
Diagnosis Age
years
Weight
kg
Hematocrit
%
Creatinine
clearance
ml/min
Total
protein
g/100 ml
Total
bilirubin
mg/100 ml
6 Gouty 62 72 46 19 7.4 0.3
nephropathy
7 Chronic 19 51 24 4 7.4 0.4
pyelonephritis
8 Chronic 19 60 23 2.8 7.0 0.3
pyelonephritis
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Table 3. Drug plasma concentrations (giml)0 and t4 values (hours)b in five anephric patients following
administration of 200 mg of doxycycline orally
Time
hours
Patient No. Mean values
1 2 3 4 5 I 2
4 2.2 3.6 1.8 1.5 2.7 1.5 3.9 2.4±0.4
1 2.5 3.5 2.0 2.2 4.8 3.0 3.9 3.1±0.4
2 4.1 6.5 4.9 3.9 6.7 3.3 4.1 4.8±0.5
4 4.2 6.6 3.5 2.8 4.3 3.7 4.5 4.2±0.5
6 3.6 4.0 3.2 2.6 4.4 3.0 3.8 3.5±0.2
12 3.1 4.0 2.9 1.9 3.3 2.5 3.3 3.0±0.3
24 2.3 3.2 2.1 1.5 2.6 1.9 3.1 2.4±0.3
36 1.5 2.7 1.8 1.1 1.6 1.0 2.1 1.7±0.2
48 1.1 1.7 0.7 0.7 1.2 0.7 1.3 1.0±0.1
72 0.5 1.0 0.5 0.2 0.2 0.3 0.4 0.4±0.1
t4 31 29 21 24 23 19 28 25
As determined by microbiological assay.b Calculated by regression analysis of plasma decay curve in first 48 hours.
Repeat studies following three-month interval.
[5] was diluted with unlabeled analytical grade
doxycycline hyclate to yield a specific activity of
4,107 PCi-mg of doxycycline base. The product was
twice recrystallized. Radiochemical purity was found
to be > 97% as established by reverse isotope dilution
techniques and radiochromatographic procedures
using a paper chromatography system. Chemical
purity was established as previously described [5]. The
radio-labeled product had the expected antibacterial
potency.
Measurements. All measurements were performed
in duplicate. Standard bioassays appropriately modi-
fied were used for determination of unchanged doxy-
cycline in plasma and urine [12]. A combustion pro-
cedure using an automatic oxidizer (Oxymat, Inter-
technique Co., Dover, New Jersey) was used to
measure radioactivity content of all plasma samples.
Dialysate aliquots, urine and feces samples were
appropriately prepared [5] and counted in a liquid
scintillator.
Results
Biologic and radioactive plasma t- in anephric
patients. The results of the studies in the five anephric
patients demonstrate a mean peak plasma doxycycline
value of 4.8 SEM 0.5 g/ml at two hours following
drug administration (Table 3). This value and the
volume of distribution of the compound are similar to
those noted when an equal quantity of doxycycline is
administered parenterally [7] and thereby indicate
• -. Radioassay
0-0 Microbiologic assay
6
5
4
3
0
I
0.5
Log0 Y'= Loge a+(k)X
0.693
k
r= —0.99
k= —0.0213
t4=32.5 hr
r= —0.99
k= —0.0278
t=24.8 hr
720 24 48
Hours (X)
Fig. 1. Serum doxycycline concentrations as determined by radio-
assayand microbiologic assay following the oral administration of
a single dose of 200 mg of 3H-doxycycline to five anephric
patients maintained on intermittent hemodialysis. Biologic and
radioactive plasma t4 values are calculated on the basis of
regression analysis of the plasma decay curves in the first 48
hours. Standard errors are included in the graph, and when the
biologic and radioactive time-concentration curves are com-
pared the difference is not significant up to 72 hours.
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Table 4. Radioactivity removed by 7 hours of hemodialysis,
72 hours after administration of a single dose of 200 mg of
3H-doxycycline
Patient No.
1 2 3 4
Mean seruma
concentration, g/ml 1.3 1.9 0.8 0.9
AmounV' dialyzed, mg 12.8 17.5 11.8 6.4
rapid and essentially complete absorption of the drug
in these studies. The studies of Fabre et a! [7] indicate
a greater than 90% absorption of doxycycline from the
gastrointestinal tract.
The mean plasma concentration data as determined
by bioassay and radioassay in our anephric patients
are detailed in Fig. I. The mean biologic plasma t
was 25 hours when calculated by regression analysis of
the plasma decay curve in the first 48 hours. In healthy
normal individuals it ranges from 15 to 25 hours
[7, 9—11]. The mean radioactive plasma t4 was 32 1/2
hours; however, the difference between the biologic
and radioactive plasma decay curves was not signifi-
cant up to 72 hours [13].
Fecal recovery. Fecal recovery of radioactivity from
the anephric patients demonstrated a mean recovery
of 77% of the administered dose (Fig. 2). Although
the stools were collected for several days, it can be
seen that most of the drug was eliminated in the first
two or three bowel movements.
Dialysance. The quantitive aspects of dialysance
of radioactivity 72 hours after doxycycline admini-
stration are summarized in Table 4. By that time most
of the drug had been eliminated from the
circulation and only small concentrations could be
detected by radioassay. Using radioassay, which
could detect smaller drug concentrations than micro-
Anephric humans
Pt. 4Pt. 3 Pt. 5
Values obtained by radioassay scintillation counting.b Expressed as drug equivalent. Approximately 50% of radio-
activity removed during hemodialysis was titrated water.
biologic assay, it was noted that when the mean
doxycycline concentration was 1.2 SEM 0.2 g/m1, a
total of 12 mg of drug equivalent (i.e., radioactive
drug and radioactive metabolites) was removed from
the systemic circulation by seven hours of hemodialysis.
Since approximately 50°/ of the radioactivity re-
moved during dialysis could be dissociated from
3H-doxycycline and identified as 3H20 by standard
analytic procedures [5], at most some 6 mg of
doxycycline could have been removed during the
course of a routine hemodialysis. Plasma clearance
rate of doxycycline was therefore 10 mI/mm or less
(Table 4).
Doxycycline plasma t4 and urinary excretion in
renal impairment. Plasma concentrations of doxy-
cycline as determined by bioassay and radioassay in
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o--o Microbiologic assay
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GFR= 19 mI/mm GFR=4 mi/mm
t=26 hr o--o '
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Fig. 2. Cumulative percent of/abel recovered from the feces offive
anephric patients who were each administered orally a single dose
of 200 mg of 3H-doxycycline. A mean 77/ of the compound was
excreted with the feces.
0.2!0 24 48 72
Hours
0 24 48 72
Hours
Fig. 3. Doxycycline serum concentrations following a single dose
of 200 mg of 3H-doxycycline ad.'ninistered orally to three patients
with varying degrees of renal impafrment. Glomerular filtration
rates (GFR) as determined by creatinine clearances are in-
cluded for each patient.
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the three patients with varying degrees of impaired
renal function are presented in Fig. 3. The plasma data
indicate that within the first 48 hours a relatively
parallel decrease in serum biologic and radioactive
potency took place.
The percentage of administered 3H-doxycycline
recovered in the urine in these patients in order of
decreasing renal function was 20.3% (patient 6),
5.6°/ (patient 7) and 2.9% (patient 8). The mean urine
concentration of biologically active doxycycline in
these patients was 7.1, 2.1 and 1.9 .tg/ml within the
first 24 hours after drug administration, and 3.6,
0.5 and 0.7 g/ml, respectively, in the 48- to 72-hour
urine collection.
Discussion
The principal objective of our studies in the anephric
individuals was achieved by the demonstration of
essentially complete gastrointestinal absorption of the
compound followed by recovery of an average of
77% of radioactivity eliminated with the feces. Pre-
vious studies with normal individuals suggest that this
radioactivity represents almost entirely unmetabolized
drug [5]. In our anephric patients an additional 6%
of the radioactive label, approximately one-half of
which represented tritiated water, was removed by
hemodialysis 72 hours following administration of the
compound, thereby giving an overall average re-
covery of some 83 of the administered drug. This
represents a high rate of recovery for single dose
pharmacokinetic studies.
In our studies most of the doxycycline eliminated
with feces probably was not secreted with bile.
Although relatively high concentrations in that fluid
have been observed, the total quantity of drug
eliminated by such a route as measured by micro-
biologic methods in humans with biliary fistulae in
the studies of Mahon, Wittenberg and Tuffnel [10] and
Fabre et al [7] have shown that less than 5% of the
totally administered compound is excreted via the
bile. In addition, the studies of Schach von Wittenau
and his associates [5, 14] have shown in an experi-
mental dog model that when using both a micro-
biologic and radioactive assay system for doxycycline
analysis less than 5% of the totally administered drug
is eliminated in the bile.
We may gain a better understanding of the fate of
doxycycline in our anephric patient studies by correla-
ting our results with the physicochemical properties
of the drug and with data derived from observations
made during animal experiments. Doxycycline com-
pared to earlier tetracyclines is more lipophilic and,
consequently, penetrates lipoid membranes with
Pharmacokinetics
events
Drug ionized
poor absorption
Drug unionized
maximal absorption
Lipid solubility
facilitates bidirectional
diffusion
Intraluminal
polyvalent cationic
chelation with
reabsorption
Fecal excretion
as ? chelated
doxycycline
Fig. 4. Suggested pharmacokinetic characte,istics of doxycycline
in the intestinal tract of anephric humans, derived from a corre-
lation of the results noted in anephric patients, the physicochemical
properties of the drug and observations made during animal
experiments.
greater ease. Like most tetracyclines it reaches its
maximum degree of lipophilicity at about pH 5.5 [14],
and animal experiments suggest that the duodenum is
the primary site of absorption [6, 15]. All tetracyclines
form complexes with metal ions [16, 17J. In the case of
doxycycline, it has been demonstrated that such
complexes are unstable in the acid contents of the
stomach, thus allowing free drug to enter the duo-
denum [6] and accounting for the fact that the
simultaneous ingestion of food and doxycycline does
not inhibit the absorption of this tetracycline from the
upper gastrointestinal tract [11]. However, when a
metal complex of the drug is formed in (or directly
introduced into) the alkaline contents of the small
intestine, it remains stable and in such form cannot
easily be absorbed [6]. In animal experiments it has
been shown that bidirectional diffusion of doxycycline
can occur across the mucosa of gastrointestinal tract
throughout the length of the small bowel and that the
net direction of such diffusion is from the serosal to the
mucosal side of the small bowel wall provided normal
intraluminal contents are present within the lumen of
the bowel [6].
Therefore, in anephric patients (Fig. 4) it is possible
to speculate that following oral administration of
doxycycline high duodenal concentrations of free drug
are achieved which allow almost complete absorption
of the compound to take place. Blood-borne doxy-
Oral
doxycydine
Blood
borne
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cycline is then presented to the serosal surface of the
small intestine and diffusion of drug into the intestinal
lumen takes place. In the lumen cationic chelation
occurs and in such form doxycycline cannot be
reabsorbed. The capacity of the intraluminal contents
to bind successive amounts of doxycycline is not
readily superseded since the daily doses of the drug
are small and new intraluminal contents are con-
stantly added to the small bowel by gastric emptying
and biliary, pancreatic and succus entericus secretions.
Minor additonal contributions to fecal elimination of
the drug are made by biliary secretion.
Thus, absorption followed by transmucosal diffu-
sion and intraluminal chelation of the compound such
that it cannot be reabsorbed appears to be a plausible
mechanism to resolve the somewhat contradictory
facts of sequential intestinal absorption followed by
excretion.
Specific information detailing the cationic binding
constants of doxycycline is not available, but it may be
assumed that doxycycline behaves qualitatively in a
manner similar to other tetracyclines [16, 17]. If
these other tetracyclines passed through the bowel
wall as easily as does doxycycline, one might expect
them to be excreted in a similar fashion. Therefore, it
does not appear to be a unique complexing ability
which causes doxycycline to be excreted with feces,
but rather its marked lipid solubility which allows
sufficiently rapid movement of the drug across the
bowel wall into the luminal contents, and the quantita-
tively small daily dosages which require elimination.
Our studies indicate that the extension of the drug's
biologic plasma t4 is minimal in otherwise stable
anephric patients maintained on intermittent dialysis.
The t-4 of radioactivity was, however, extended to a
value of 32+ hours (Fig. 2), indicating the presence of
nonbioactive compounds in small concentration in the
plasma. Whether these trace amounts of nonbio-
logically active metabolites represent tritiated water
alone or tritiated water in addition to nonbioligically
active metabolites of doxycycline cannot be resolved
at present since it is not possible to calculate the
absolute quantity of nonbioactive material as its
volume of distribution and identity are unknown. One
of the risks inherent in the use of triated drugs for
drug metabolism studies is the possibility of generating
radioactive compounds not related to the original drug.
This may occur by the transfer of the 3H label to
plasma water or by enzymatic transfer of the tritium
label to natural body constituents without generating
extracellular tritiated water [18, 19]. In the case of
doxycycline, the formation of small quantities of
triated water has been established [5]. The quantities
of nonbioactive materials involved in these studies
were minimal and the experience to date following
repetitive administration of the compound suggests
that they are of no clinical significance.
In the patients with impaired renal function, the
plasma t+ of bioactive drug (Table 3) was similar to
that noted in the anephric patients, and the renal
clearance of the drug was directly correlated with the
degree of reduction in the patient's glomerular
filtration rate.
As yet there are no clinical reports of doxycycline
inducing prerenal azotemia by the mechanisms com-
mon to other tetracyclines [21, 21].
In conclusion, these studies demonstrate that in the
anephric state or in the presence of renal impairment,
the extension of the drug's biologic plasma t+ is not
clinically significant. This finding in association with
the results of repetitive dosing studies as reported by
other investigators [9, 10] suggests that no alteration
in the usual therapeutic drug regimen is necessary
when this compound is used in the absence of renal
function. Removal rate of the drug by hemodialysis is
not of therapeutic significance. In addition, our
investigations more clearly identify in humans the
nonrenal, nonhepatic, gastrointestinal pathway of
doxycycline excretion. This drug therefore appears to
be unique among the tetracyclines in that when renal
failure complicates the clinical picture doxycycline may
be used as a drug of choice if a tetracycline is indicated
for the therapy of systemic infection.
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